{"id":"naloxone-hydrochloride-injection-usp","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute withdrawal syndrome (agitation, body aches, sweating)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":{"setId":"b5463553-b775-47a3-8d10-31e01ca1ec72","title":"NALOXONE HYDROCHLORIDE INJECTION, USP, AUTO-INJECTOR (NALOXONE HYDROCHLORIDE) INJECTION, SOLUTION [KALEO, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone is a non-selective opioid antagonist that binds with high affinity to mu, delta, and kappa opioid receptors, displacing opioid agonists and preventing their effects. By blocking opioid receptor activation, it reverses respiratory depression, sedation, and other life-threatening effects of opioid overdose. Its rapid onset and short duration make it ideal for emergency reversal of acute opioid toxicity.","oneSentence":"Naloxone competitively blocks opioid receptors to rapidly reverse opioid overdose and restore normal breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:16:49.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of opioid overdose (acute opioid toxicity)"},{"name":"Reversal of opioid-induced respiratory depression"}]},"trialDetails":[{"nctId":"NCT05264493","phase":"PHASE1","title":"Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-10-06","conditions":"Healthy Volunteers","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20230403","type":"SUPPL","sponsor":"KALEO INC","applicationNumber":"NDA215457"},{"date":"20220228","type":"ORIG","sponsor":"KALEO INC","applicationNumber":"NDA215457"}],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Naloxone Hydrochloride Injection, USP","genericName":"Naloxone Hydrochloride Injection, USP","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone competitively blocks opioid receptors in the central nervous system, rapidly reversing the effects of opioid overdose. Used for Reversal of opioid overdose and opioid-induced respiratory depression, Emergency treatment of known or suspected opioid poisoning.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}